Scenic Biotech Partners with Ono Pharmaceutical to Advance Novel Target Discovery Using Cell-Seq Platform
核心洞察
Scenic Biotech (搜索) announced a license and research agreement with Ono Pharmaceutical to utilize its Cell-Seq platform (搜索) for discovering novel therapeutic targets.
This collaboration represents Scenic's fourth Cell-Seq partnership with a major pharmaceutical company, joining existing agreements with Genentech, Bristol Myers Squibb (搜索), and Alnylam.
The partnership validates Scenic's modifier therapy approach, which targets secondary genes to rebalance health rather than addressing primary disease-causing mutations directly.
Scenic Biotech (搜索), a pioneer in modifier therapies for severe diseases, has entered into a license and research agreement with Ono Pharmaceutical Co., Ltd. to leverage its proprietary Cell-Seq platform (搜索) for novel therapeutic target discovery. The collaboration, announced on January 7, 2026, marks a significant expansion of Scenic's platform partnerships in the pharmaceutical industry.
Strategic Platform Validation
The agreement represents the fourth Cell-Seq collaboration for Scenic Biotech (搜索) with a major pharmaceutical company, joining ongoing multi-year partnerships with Genentech, Bristol Myers Squibb (搜索), and Alnylam. This growing portfolio of collaborations demonstrates increasing industry recognition of the platform's potential to identify new therapeutic opportunities.
"This collaboration with Ono Pharmaceutical represents another strong validation of our platform's ability to uncover new disease biology and identify novel targets for rare and common indications," said Roland W. Bürli, PhD, Chief Scientific Officer of Scenic Biotech (搜索). "In parallel with advancing our proprietary pipeline of first-in-class, disease-modifying therapies toward the clinic, we continue to leverage collaborations with leading pharmaceutical partners to unlock the full potential of our Cell-Seq platform (搜索)."
Modifier Therapy Approach
Scenic Biotech (搜索)'s approach centers on modifier therapy, which represents a departure from traditional therapeutic strategies. Rather than targeting primary disease-causing mutations directly, modifier therapy seeks to rebalance health by acting on secondary genes that can improve or potentially bypass disease impact entirely. This approach aims to achieve therapeutic effects through alternative pathways in the genome.
The company's robust pipeline, derived from its proprietary Cell-Seq platform (搜索), includes wholly owned small molecule programs alongside strategic collaborations with multinational pharmaceutical leaders. By unlocking new genomic pathways, Scenic is developing a range of modifier therapies designed to address patient needs across various disease areas.
Partnership Focus Areas
Ono Pharmaceutical brings expertise in areas with significant unmet medical needs, including oncology, immunology, and neurology. The company's philosophy of being "Dedicated to the Fight against Disease and Pain" aligns with its strategy of fostering partnerships with academic and biotech organizations to accelerate drug discovery efforts.
Through its affiliate Deciphera Pharmaceuticals (搜索), Ono Pharmaceutical is expanding clinical development and commercial operations in the US and Europe, supporting global business expansion and reinforcing its commitment to patient care. This international presence may provide additional opportunities for advancing discoveries made through the Scenic collaboration.
The partnership underscores the growing interest in platform-based approaches to drug discovery, particularly those that can identify novel biological targets across multiple therapeutic areas. As Scenic continues to advance its proprietary programs toward clinical development, these collaborative agreements provide validation of the Cell-Seq platform (搜索)'s potential while generating additional resources to support the company's research efforts.